This is a working overview of Synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-20 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
In 2000, Wesley Enoch wrote and directed a modern adaptation titled Black Medea, which was first produced by Sydney Theatre Company's Blueprint at the Wharf 2 Theatre, Sydney, on 19 August 2000. Nathan Ramsay played the part of Jason, Tessa Rose played Medea, and Justine Saunders played the Chorus. Medea is re-characterised as an indigenous woman transported from her homeland to the city and about to be abandoned by her abusive social-climbing husband. Tom Lanoye (2001) used the story of Medea to bring up modern problems (such as migration and man vs. woman), resulting in a modernized version of Medea. His version also aims to analyze ideas such as the love that develops from the initial passion, problems in the marriage, and the "final hour" of the love between Jason and Medea. Roger Kirby's 2004 adaptation of the play, Medea in Jerusalem, was set in modern day Israel, and featured an Israeli-Jewish Jason and a Palestinian Medea who opts to turn her children into suicide bombers after being divorced by Jason. It premiered at the Rattlestick Playwrights Theatre in New York City. Kristina Leach adapted the story for her play The Medea Project, which had its world premiere at the Hunger Artists Theatre Company in 2004 and placed the story in a modern-day setting. Peter Stein directed Medea in Epidaurus 2005. Irish playwright Marina Carr's By the Bog of Cats is a modern re-telling of Euripides' Medea. In November 2008, Theatre Arcadia, under the direction of Katerina Paliou, staged Medea at the Bibliotheca Alexandrina (University of Alexandria, Egypt).
== Use and effects == According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), ETH-LAD has a dose of 40 to 150 μg orally and a duration of 8 to 12 hours. However, it also produced clear effects at a dose of 20 μg, and in other publications, Shulgin gave a lower dose range for the drug of 40 to 80 μg. Its onset ranges from 15 minutes to 1 hour and peak effects occur after about 1 to 2 hours. Shulgin has stated that ETH-LAD is "a little more potent" than LSD or roughly twice as potent as LSD in humans. Other researchers have described it as "slightly more potent" or "somewhat more potent" than LSD in humans. For comparison, Shulgin lists the dose range of LSD as 60 to 200 μg or 50 to 200 μg in his publications. Based on the preceding findings, ETH-LAD is one of the most potent serotonergic psychedelics known in humans, if not the most potent known psychedelic. As a result of this, it has been said that LSD can no longer be considered the most potent psychedelic. The effects of ETH-LAD have been reported to include closed-eye imagery, very few visual changes or distortions, gentle movements of objects, LSD-like visual aspects, two-dimensional surfaces looking three-dimensional, objects looking "magical", and possible time slowing. It was described as making the body feel balanced, thinking being easy, concepts easy to follow through, mind capable of realistic and down-to-earth thought, and warmth and humor being present.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{6}_{4}Be->[5\ {\ce {zs}}]{^{4}_{2}He}+{2_{1}^{1}H}}}\\{\ce {{^{7}_{4}Be}+e^{-}->[53.22\ {\ce {d}}]{^{7}_{3}Li}}}\\{\ce {^{8}_{4}Be->[81.9\ {\ce {as}}]{2_{2}^{4}He}}}\\{\ce {^{10}_{4}Be->[1.387\ {\ce {Ma}}]{^{10}_{5}B}+e^{-}}}\\{\ce {^{11}_{4}Be->[13.76\ {\ce {s}}]{^{11}_{5}B}+e^{-}}}\\{\ce {^{11}_{4}Be->[13.76\ {\ce {s}}]{^{7}_{3}Li}+{^{4}_{2}He}+e^{-}}}\\{\ce {^{12}_{4}Be->[21.46\ {\ce {ms}}]{^{12}_{5}B}+e^{-}}}\\{\ce {^{12}_{4}Be->[21.46\ {\ce {ms}}]{^{11}_{5}B}+{^{1}_{0}n}+e^{-}}}\\{\ce {^{13}_{4}Be->[1\ {\ce {zs}}]{^{12}_{4}Be}+{^{1}_{0}n}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{13}_{5}B}+{^{1}_{0}n}+e^{-}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{14}_{5}B}+e^{-}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{12}_{5}B}+{2_{0}^{1}n}+e^{-}}}\\{\ce {^{15}_{4}Be->[790\ {\ce {ys}}]{^{14}_{4}Be}+{^{1}_{0}n}}}\\{}{\ce {^{16}_{4}Be->[650\ {\ce {ys}}]{^{14}_{4}Be}+{2_{0}^{1}n}}}\\{}\end{array}}}
Lente insulin (derived from the Italian word lento, meaning "slow"), also known as insulin zinc suspension, was an intermediate-acting insulin that is no longer used in humans. Its effects begin one to two hours after administration, with peak activity occurring approximately 8 to 12 hours post-injection, and some residual effects lasting beyond 24 hours. Manufacturers discontinued Lente insulin and other similar insulin analogs in the mid-2000s, and it is no longer approved for human use in the United States. This decision was partly due to the medical community's preference for more predictable insulin formulations, such as recombinant NPH insulin. Similarly to the modern brands of NPH and regular insulin, which are still sold, lente insulins would be marketed under the name of the rest of the insulins in a brand's product line, followed by the letter L.
Sources: en.wikipedia.org
== Effects against senescent cells == In animal studies, navitoclax was found to be a senolytic agent, inducing apoptosis in senescent, but not non-senescent cells. Oral administration of navitoclax (ABT-263) to either sublethally irradiated or normally aged mice reduced senescent cells, including senescent bone marrow hematopoietic stem cells and senescent muscle stem cells. This depletion mitigated total-body irradiation-induced premature aging of the hematopoietic system and rejuvenated the aged hematopoietic stem cells and muscle stem cells in normally aged mice. On September 19, 2018, an article was published in Nature about using navitoclax to kill senescent glial cells in mice. The drug had a protective effect against memory loss in mice genetically engineered to simulate Alzheimer's disease. On December 3, 2024, an article was published in Aging detailing a study investigating the effects of topical navitoclax (ABT-263) on aged mouse skin. It examined whether eliminating senescent cells could improve wound healing. In the study, 24-month-old mice were treated with topical navitoclax (ABT-263) for five days. The treatment reduced the expression of senescence markers p16 and p21 and decreased the number of SA-β-gal– and p21-positive cells compared with DMSO controls. Navitoclax (ABT-263) application also induced a transient inflammatory response and macrophage infiltration. Bulk RNA sequencing revealed upregulation of genes involved in wound-healing pathways, including inflammation, angiogenesis, collagen synthesis, and extracellular matrix remodeling.
Gotcha! (1985 film) is a film about a college student named Jonathan (Anthony Edwards) who plays a game called Gotcha in which he hunts and is hunted by other students with paint guns on campus. Jonathan goes to France on vacation, meets a beautiful woman named Sasha (Linda Fiorentino), travels with her to East Germany, and unknowingly becomes involved in the spy game between the US and USSR. The Kremlin Letter is a 1970 American neo-noir espionage thriller set in the winter of 1969–1970, at the height of US-Soviet tensions. No Way Out a 1987 film about a spy myth that is created to cover up the killing of the mistress of a high American official.
Extremophile – Organisms capable of living in extreme environments Ombrophobe – Plant adverse to rainfall Osmophile – Organism tolerant osmotic effects from a low water activity Xerocole – Any animal adapted to live in the desert Xerophyte – A plant adapted to a hot dry environment
=== Reverse electron flow === Reverse electron flow is the transfer of electrons through the electron transport chain through the reverse redox reactions. Usually requiring a significant amount of energy to be used, this can reduce the oxidized forms of electron donors. For example, NAD+ can be reduced to NADH by Complex I. There are several factors that have been shown to induce reverse electron flow. However, more work needs to be done to confirm this. One example is blockage of ATP synthase, resulting in a build-up of protons and therefore a higher proton-motive force, inducing reverse electron flow.
The relatively quick heteronuclear single quantum correlation experiment helps determine the feasibility of doing subsequent longer, more expensive, and more elaborate experiments. It is not possible to assign peaks to specific atoms from the heteronuclear single quantum correlation alone.
Sources: en.wikipedia.org
LED airport fixtures currently include medium-intensity runway lights, runway centerline lights, taxiway centerline and edge lights, guidance signs, and obstruction lighting. LEDs are also used as a light source for DLP projectors, and to backlight newer LCD television (referred to as LED TV), computer monitor (including laptop) and handheld device LCDs, succeeding older CCFL-backlit LCDs although being superseded by OLED screens. RGB LEDs raise the color gamut by as much as 45%. Screens for TV and computer displays can be made thinner using LEDs for backlighting. LEDs are small, durable and need little power, so they are used in handheld devices such as flashlights. LED strobe lights or camera flashes operate at a safe, low voltage, instead of the 250+ volts commonly found in xenon flashlamp-based lighting. This is especially useful in cameras on mobile phones, where space is at a premium and bulky voltage-raising circuitry is undesirable. LEDs are used for infrared illumination in night vision uses including security cameras. A ring of LEDs around a video camera, aimed forward into a retroreflective background, allows chroma keying in video productions.
Ralph William James Rimmer. Lately Chief Executive Officer, Rugby Football League. For services to Rugby League Football. Dr. Lisa Margaret Ritchie. Head of Infection Prevention and Control, NHS England. For services to Healthcare, particularly during Covid-19. Michael Thomas Robinson. Chief Executive, Royal Scottish Geographical Society. For services to Climate Change Education. Professor Colva Mary Roney-Dougal. Professor of Mathematics, University of St Andrews. For services to Education and Mathematics. Kenneth James Gordon Harvey Ross. Founding Officer, National Down Syndrome Policy Group. For services to Charity, to Education and to People with Down Syndrome. Diane Rosalie Aldworth Ruddock. For services to the Environment, to Heritage and to the community in Northern Ireland. John Hamilton Ryley. Lately Head of News, Sky News. For services to Journalism. Clovis Constantine Salmon. Documentary Filmmaker. For services to Culture and to the Black Community. William Henry Salomon. President, Young Enterprise. For services to Education. Carolyn Margaret Sampson. Soprano. For services to Music. Steven Ross Savory. Chief Executive Officer, Gloucestershire Learning Alliance. For services to Education. Professor Ulrike Hermine Schmidt. Professor of Eating Disorders, King's College London and Consultant Psychiatrist, South London and Maudsley NHS Foundation Trust. For services to People with Eating Disorders. Ian Charles Sears. Commercial Specialist, Cabinet Office. For Public Service. Ruth Victoria Shaw. Chief Executive Officer, Premier League Charitable Fund.
A reference range in medicine is the range or the interval of values that is deemed normal for a physiological measurement in healthy persons (for example, the amount of creatinine in the blood, or the partial pressure of oxygen). It is a basis for comparison for a physician or other health professional to interpret a set of test results for a particular patient. Some important reference ranges in medicine are reference ranges for blood tests and reference ranges for urine tests.
The receptors for enkephalin are the δ-opioid receptor (DOR) and μ-opioid receptor (MOR). Opioid receptors are a group of G-protein-coupled receptors, with other opioids as ligands as well. The other endogenous opioids are dynorphins (that bind to κ-opioid receptor), endorphins (MOR), endomorphins, and nociceptin-orphanin FQ. The opioid receptors are ~40% identical to somatostatin receptors (SSTRs).
== Practice of therapeutic drug monitoring == Automated analytical methods such as enzyme multiplied immunoassay technique or fluorescence polarization immunoassay are widely available in medical laboratories for drugs frequently measured in practice. Nowadays, most other drugs can be readily measured in blood or plasma using versatile methods such as liquid chromatography–mass spectrometry or gas chromatography–mass spectrometry, which progressively replaced high-performance liquid chromatography. Yet, TDM is not limited to the provision of precise and accurate concentration measurement results, it also involves appropriate medical interpretation, based on robust scientific knowledge. In order to guarantee the quality of this clinical interpretation, it is essential that the sample be taken under good conditions: i.e., preferably under a stable dosage, at a standardized sampling time (often at the end of a dosing interval), excluding any source of bias (sample contamination or dilution, analytical interferences) and having carefully recorded the sampling time, the last dose intake time, the current dosage and the influential patient's characteristics.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.